These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 30123922)
1. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922 [TBL] [Abstract][Full Text] [Related]
2. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691 [TBL] [Abstract][Full Text] [Related]
3. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT. Park S; Lee Y; Kim TS; Kim SK; Han JY Medicine (Baltimore); 2020 Dec; 99(51):e23815. PubMed ID: 33371161 [TBL] [Abstract][Full Text] [Related]
4. Predictive value and accuracy of [ Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669 [TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160 [No Abstract] [Full Text] [Related]
7. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of [ Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131 [TBL] [Abstract][Full Text] [Related]
9. Tumor response assessment on imaging following immunotherapy. Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R Front Oncol; 2022; 12():982983. PubMed ID: 36387133 [TBL] [Abstract][Full Text] [Related]
10. Assessment of early metabolic progression in melanoma patients under immunotherapy: an Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal studies of the Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898 [TBL] [Abstract][Full Text] [Related]
12. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Wachsmann JW; Ganti R; Peng F Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005 [TBL] [Abstract][Full Text] [Related]
13. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739 [TBL] [Abstract][Full Text] [Related]
14. Organ-specific accuracy of [ Gideonse BM; Birkeland M; Vilstrup MH; Grupe P; Naghavi-Behzad M; Ruhlmann CH; Gerke O; Hildebrandt MG Jpn J Radiol; 2024 Jul; 42(7):753-764. PubMed ID: 38504000 [TBL] [Abstract][Full Text] [Related]
15. The role of interim Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079 [TBL] [Abstract][Full Text] [Related]
16. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381 [TBL] [Abstract][Full Text] [Related]
17. Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661 [TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306 [TBL] [Abstract][Full Text] [Related]
19. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Castello A; Lopci E Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440 [TBL] [Abstract][Full Text] [Related]
20. Can benign lymphoid tissue changes in Sachpekidis C; Larribère L; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2019 Feb; 68(2):297-303. PubMed ID: 30478475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]